Ainos Inc.
AIMD evidence brief
What we can confirm
- BioSniper Score:
- 6.1 / 10
- Market Cap:
- $10.6M
- Lead Asset:
- veldona (Phase 2)
What it means
What to watch
Prepared research question
What matters most for AIMD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AIMD
Ainos Inc. (AIMD) is a dual-platform biotech company developing an AI-based scent digitization platform (AI Nose) and an oral interferon therapeutic platform (VELDONA), with clinical programs in oral warts, Sjögren's syndrome, and feline chronic gingivostomatitis, and no current product revenue.
Key risk: Cash runway risk
BioSniper Score
Based on 4 of 6 signals
Market Cap
$10.6M
Cash Runway
—
Lead Asset
veldona (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Ainos Inc..
Ainos Inc. (AIMD) is a dual-platform biotech company developing an AI-based scent digitization platform (AI Nose) and an oral interferon therapeutic platform (VELDONA), with clinical programs in oral warts, Sjögren's syndrome, and feline chronic gingivostomatitis, and no current product revenue.
- Ainos operates three core platforms: AI Nose (scent digitization), POCT (point-of-care testing), and VELDONA (oral interferon therapeutics) [sec_mda · as of 2025-08-13].
- VELDONA has received U.S. FDA Orphan Drug Designation for oral warts in HIV-seropositive patients [sec_mda · as of 2025-08-13].
- As of 2026-06-30, the company reported cash & equivalents of $1.4M, zero revenue, a net loss of -$4.6M, and shareholders' equity of $3.3M [sec].
- Clinical studies for VELDONA are underway in Taiwan for oral warts (HIV+), Sjögren's syndrome, and feline chronic gingivostomatitis [sec_mda · as of 2025-08-13].
- AI Nose applications are being developed for senior care, hospital infrastructure, and exhaled breath analysis, but remain in research/validation stage [sec_mda · as of 2026-08-03].
What works
- VELDONA has secured U.S. FDA Orphan Drug Designation for oral warts in HIV-seropositive patients, which may provide market exclusivity and development incentives [sec_mda · as of 2025-08-13].
- The company has a diversified pipeline across three platforms (AI Nose, POCT, VELDONA) targeting multiple indications, including rare diseases and veterinary health [sec_mda · as of 2025-08-13].
- Ainos has raised capital through at-the-market offerings and loan financing, with $3.4M in financing proceeds in H1 2026 [sec_mda · as of 2026-08-03].
What to weigh
- The company has zero product revenue as of 2026-06-30 and reported a net loss of -$4.6M, with cash reserves of only $1.4M [sec].
- AI Nose applications remain in research/validation stage with no commercial adoption yet; the company notes that benefits may take time to reflect in revenue [sec_mda · as of 2026-08-03].
- Ainos acknowledges there is no assurance of achieving profitability and may need additional capital if current efforts fail [sec_mda · as of 2026-05-13].
- The VELDONA clinical programs are in Phase 2 and rely on Taiwan-based studies; regulatory and enrollment uncertainties persist [sec_mda · as of 2025-08-13].
From the filings
Quoted directly from source documents.
Ainos is a dual-platform company advancing AI smelltech and immune therapeutics.
“Ainos, Inc. (the "Company"), incorporated in the State of Texas in 1984, is a dual-platform company advancing artificial intelligence-based smelltech technologies and immune therapeutics.”
SEC MD&A · March 30, 2026
VELDONA has FDA Orphan Drug Designation for oral warts in HIV-seropositive patients.
“The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for our VELDONA formulation as a potential treatment for oral warts in HIV-seropositive patients.”
SEC MD&A · August 13, 2025
As of December 31, 2025, the company had cash of $417,353.
“As of December 31, 2025, the Company had cash and cash equivalents of $417,353.”
SEC MD&A · March 30, 2026
Risks & what to watch (4)›
Key risks
- Cash runway risk — Cash of $1.4M as of 2026-06-30 with zero revenue and ongoing net losses may fund operations for less than 12 months [sec].
- No commercial revenue — Zero product revenue as of 2026-06-30; AI Nose still in validation stage and VELDONA in Phase 2 [sec].
- Clinical and regulatory uncertainty — VELDONA trials in Taiwan for oral warts and Sjögren's syndrome face enrollment and regulatory hurdles [sec_mda · as of 2025-08-13].
- Dependence on additional financing — Company states it may need further equity/debt financing if profitability not achieved [sec_mda · as of 2026-05-13].
What to watch
- Progress of VELDONA Phase 2 trials in Taiwan for oral warts (HIV+) and Sjögren's syndrome [sec_mda · as of 2025-08-13].
- Commercial pilot phase for AI Nose in industrial, robotics, and long-term care settings [sec_mda · as of 2025-11-13].
- Cash position and any new financing rounds or at-the-market offerings [sec_mda · as of 2026-08-03].
- Potential out-licensing partnerships for VELDONA [sec_mda · as of 2026-03-30].
Sources: Pipeline · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run Ainos Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Ainos Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 4.96 · 0% dilution
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
9 buys · 6 sells (180d)
Pipeline
Financials
Short Interest
as of May 20, 2026- % of float
- 0.6%
- Days to cover
- 0.8
- Shares short
- 21,702
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AIMD short interestGovernance
Frequently asked questions
What is the AI investment thesis for Ainos Inc.?
Ainos Inc. (AIMD) is a dual-platform biotech company developing an AI-based scent digitization platform (AI Nose) and an oral interferon therapeutic platform (VELDONA), with clinical programs in oral warts, Sjögren's syndrome, and feline chronic gingivostomatitis, and no current product revenue.
What is Ainos Inc.'s lead drug candidate?
Ainos Inc.'s most advanced tracked candidate is veldona (Phase 2) for feline chronic gingivostomatitis (FCGS).
Who is the CEO of Ainos Inc.?
Mr. Chun-Hsien Tsai is the chief executive officer of Ainos Inc. (AIMD).
Where is Ainos Inc. headquartered?
Ainos Inc. (AIMD) is headquartered in Houston, TX, United States.
What therapeutic areas does Ainos Inc. focus on?
Ainos Inc. develops therapies across Oncology, Infectious Disease, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.